LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,092
تعداد مقالات10,022
تعداد مشاهده مقاله27,179,613
تعداد دریافت فایل اصل مقاله7,455,550
Mazloom, Zohreh, Dabbaghmanesh, Mohammad Hossein, Moazen, Mahsa, Bagheri, Sara. (1394). Supplementation with Glucosamine Has no Adverse Effects on Glycemic Level and Insulin Resistance in Type 2 Diabetic Patients. سامانه مدیریت نشریات علمی, 3(4), 146-152.
Zohreh Mazloom; Mohammad Hossein Dabbaghmanesh; Mahsa Moazen; Sara Bagheri. "Supplementation with Glucosamine Has no Adverse Effects on Glycemic Level and Insulin Resistance in Type 2 Diabetic Patients". سامانه مدیریت نشریات علمی, 3, 4, 1394, 146-152.
Mazloom, Zohreh, Dabbaghmanesh, Mohammad Hossein, Moazen, Mahsa, Bagheri, Sara. (1394). 'Supplementation with Glucosamine Has no Adverse Effects on Glycemic Level and Insulin Resistance in Type 2 Diabetic Patients', سامانه مدیریت نشریات علمی, 3(4), pp. 146-152.
Mazloom, Zohreh, Dabbaghmanesh, Mohammad Hossein, Moazen, Mahsa, Bagheri, Sara. Supplementation with Glucosamine Has no Adverse Effects on Glycemic Level and Insulin Resistance in Type 2 Diabetic Patients. سامانه مدیریت نشریات علمی, 1394; 3(4): 146-152.

Supplementation with Glucosamine Has no Adverse Effects on Glycemic Level and Insulin Resistance in Type 2 Diabetic Patients

Journal of Health Sciences & Surveillance System
مقاله 4، دوره 3، شماره 4، دی 2015، صفحه 146-152    اصل مقاله (339.47 K)
نوع مقاله: Original Articles
نویسندگان
Zohreh Mazloom* 1؛ Mohammad Hossein Dabbaghmanesh2؛ Mahsa Moazen3؛ Sara Bagheri4
1Professor, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran;
2Professor, Endocrine and Metabolism Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran;
3PhD Candidate, Student Research Committee, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran;
4MSc, Student Research Committee, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
چکیده
Background: Use of glucosamine as an alternative treatment for osteoarthritis is becoming more frequent, including in those who have diabetes at the same time. The results from in vitro and animal studies propose that glucosamine may inversely affect glucose metabolism. However, the recommended dose of oral glucosamine in healthy people or diabetics did not have such effects consistently. The aim of the present study was to assess the effect of glucosamine on glycemic control and insulin resistance in type 2 diabetic patients. Methods: Fifty-four patients with type 2 diabetes participated in this randomized, double-blind, placebo-controlled study. The participants were assigned to receive 1500 mg glucosamine hydrochloride or placebo for 12 weeks. After determining their baseline characteristics, body mass index and dietary intake components, fasting blood glucose and fasting insulin were measured at weeks of 0, 8, and 12. Indices of insulin function including quantitative insulin sensitivity check index (QUICKI) and homeostasis model assessment of insulin resistance (HOMA-IR) were calculated by specific formulas. Independent t-test and general linear model repeated measures were used to analyze the data. Results: In the glucosamine group, the means of fasting blood glucose and insulin were 107.31±24.07 mg/dl and 8.75±4.37 μu/ ml, respectively at baseline, which reached 112.38±31.50 and 9.10±4.17 at week 12. In the placebo group, the mean for fasting blood glucose and insulin were 103.84±24.15 and 9.79±4.02 at the beginning of the study, which reached to 111.40±26.43 and 8.58±3.68 at week 12. The results showed that there were no significant differences in fasting blood glucose, insulin, HOMA-IR and QUICKI indices at all the studied time points (weeks of 0, 8 and 12) within or between the groups. Conclusion: Twelve weeks of a normal recommended dose of glucosamine supplements may not have adverse effects on glycemic control and insulin resistance in type 2 diabetic patients.Trial registration number: IRCT2014031811785N2.
کلیدواژه‌ها
diabetes mellitus؛ Glucosamine؛ Blood glucose؛ Insulin Resistance
مراجع
  1. Rahimi R, Nikfar S, Larijani B, Abdollahi M. A review
  2. on the role of antioxidants in the management of
  3. diabetes and its complications. Biomed Pharmacother
  4. ; 59(7): 365-73.
  5. Oh S, Kalyani RR, Dobs A. Nutritional management of
  6. diabetes mellitus. In: Ross AC, Caballero B, Cousins
  7. RJ, Tucker KL, Ziegler TR. Modern nutrition in health
  8. and disease. 11th ed. Philadelphia: Lippincott Williams
  9. & Wilkins; 2014.
  10. Gomez FE, Kaufer-Horwitz M. Medical nutrition
  11. therapy for rheumatic disease. In: Mahan LK, Escott-
  12. Stump S, Raymond J. Krause’s food and the nutrition
  13. care process. 13th ed. St. Louis, Mo: Elsevier/Saunders;
  15. Scroggie DA, Albright A, Harris MD. The effect
  16. of glucosamine-chondroitin supplementation on
  17. glycosylated hemoglobin levels in patients with type
  18. diabetes mellitus: a placebo-controlled, doubleblinded,
  19. randomized clinical trial. Arch Intern Med
  20. ; 163(13): 1587-90.
  21. Rahman N, Penm E, Bhatia K. Arthritis and
  22. musculoskeletal conditions in Australia 2005, with
  23. a focus on osteoarthritis, rheumatoid arthritis and
  24. osteoporosis/ Australian Institute of Health and
  25. Welfare. Canberra: 2005.
  26. Anderson JW, Nicolosi RJ, Borzelleca JF. Glucosamine
  27. effects in humans: a review of effects on glucose
  28. metabolism, side effects, safety considerations and
  29. efficacy. Food Chem Toxicol 2005; 43(2): 187-201.
  30. Al-Saeed A. Gastrointestinal and cardiovascular risk
  31. of nonsteroidal anti-inflammatory drugs. Oman Med
  32. J 2011; 26(6): 385-91.
  33. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune
  34. E, Bruyere O, et al. Long-term effects of glucosamine
  35. sulphate on osteoarthritis progression: a randomised,
  36. placebo-controlled clinical trial. Lancet 2001;
  37. (9252): 251-6.
  38. Derfoul A, Miyoshi AD, Freeman DE, Tuan RS.
  39. Glucosamine promotes chondrogenic phenotype in
  40. both chondrocytes and mesenchymal stem cells and
  41. inhibits MMP-13 expression and matrix degradation.
  42. Osteoarthritis Cartilage 2007; 15(6): 646-55.
  43. Yu JG, Boies SM, Olefsky JM. The effect of oral
  44. glucosamine sulfate on insulin sensitivity in human
  45. subjects. Diabetes Care 2003; 26(6): 1941-2.
  46. Stumpf JL, Lin SW. Effect of glucosamine on glucose
  47. control. Ann Pharmacother 2006; 40(4): 694-8.
  48. Tannis AJ, Barban J, Conquer JA. Effect of glucosamine
  49. supplementation on fasting and non-fasting plasma
  50. glucose and serum insulin concentrations in healthy
  51. individuals. Osteoarthritis Cartilage 2004; 12(6):
  52. -11.
  53. Nakaishi Y, Bando M, Shimizu H, Watanabe K,
  54. Goto F, Tsuge H, et al. Structural analysis of human
  55. glutamine:fructose-6-phosphate amidotransferase, a
  56. key regulator in type 2 diabetes. FEBS Lett 2009;
  57. (1): 163-7.
  58. Munoz N. Glucosamine reduces glycogen storage in L6
  59. skeletal muscle cells [MSc thesis]: Washington State
  60. University; 2007.
  61. Hawkins M, Hu M, Yu J, Eder H, Vuguin P, She L, et al.
  62. Discordant effects of glucosamine on insulin-stimulated
  63. glucose metabolism and phosphatidylinositol 3-kinase
  64. activity. J Biol Chem 1999; 274(44): 31312-9.
  65. Dostrovsky NR, Towheed TE, Hudson RW,
  66. Anastassiades TP. The effect of glucosamine on glucose
  67. metabolism in humans: a systematic review of the
  68. literature. Osteoarthritis Cartilage 2011; 19(4): 375-80.
  69. Albert SG, Oiknine RF, Parseghian S, Mooradian AD,
  70. Haas MJ, McPherson T. The effect of glucosamine on
  71. Serum HDL cholesterol and apolipoprotein AI levels
  72. in people with diabetes. Diabetes Care 2007; 30(11):
  73. -3.
  74. Namvaran F, Azarpira N, Rahimi-Moghaddam P,
  75. Dabbaghmanesh MH. Polymorphism of peroxisome
  76. proliferator-activated receptor γ (PPARγ) Pro12Ala in
  77. the Iranian population: relation with insulin resistance
  78. and response to treatment with pioglitazone in type 2
  79. diabetes. Eur J Pharmacol 2011; 671(1-3): 1-6.
  80. Pouwels MJ, Jacobs JR, Span PN, Lutterman JA, Smits
  81. P, Tack CJ. Short-term glucosamine infusion does not
  82. affect insulin sensitivity in humans. J Clin Endocrinol
  83. Metab 2001; 86(5): 2099-103.
  84. Monauni T, Zenti MG, Cretti A, Daniels MC, Targher
  85. G, Caruso B,et al. Effects of glucosamine infusion on
  86. insulin secretion and insulin action in humans. Diabetes
  87. ; 49(6): 926-35.
  88. Biggee BA, Blinn CM, Nuite M, Silbert JE, McAlindon
  89. TE. Effects of oral glucosamine sulphate on serum
  90. glucose and insulin during an oral glucose tolerance
  91. test of subjects with osteoarthritis. Ann Rheum Dis
  92. ; 66(2): 260-2.
  93. Singh B, Saxena A. Surrogate markers of insulin
  94. resistance: A review. World J Diabetes 2010; 1(2): 36-47.
آمار
تعداد مشاهده مقاله: 1,404
تعداد دریافت فایل اصل مقاله: 358


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب